Abstract
Parkinson’s disease is the second most prevalent neurodegenerative disease and a rising problem worldwide, where the lack of early and specific diagnosis is causing significant
concerns. To date, diagnosis relies on clinical determination of symptoms that may develop decades after the disease’s onset. Biomarkers reflecting the progression of Parkinson’s disease
have arisen as potential diagnostic targets, such as 𝛼-Synuclein (𝛼-SN) aggregates. 𝛼-SN oligomers are small aggregated species which play a key role in disease initiation and progression.
These appear promising biomarkers for early detection, although specific targeting remains challenging.
Nucleic acid technology has transpired in diagnostic applications due to its unique properties of self-assembly and sequence programmability, facilitated by Watson-Crick base pairing, along
with the possibility of easy chemical functionalisation. Nucleic acids are commonly applied in biosensing and target recognition, as they can be utilised to build various architectures, either
binding a target specifically, such as aptamers, or scaffolding known binding partners.
This thesis presents three projects approaching specific targeting of 𝛼-SN by employing the functionalisation of nucleic acids. In the first project, RNA was modified in a site-specific manner
using small molecules reported to interact with 𝛼-SN. The modifications were incorporated, using the RNA as a spatially designed scaffold or employing systematic evolution of ligands
by exponential enrichment (SELEX) for specific targeting of 𝛼-SN. The incorporation of modifications did increase interactions of 𝛼-SN, though specificity was not obtained. The second
project applied the conjugation of known 𝛼-SN binding partners to DNA oligonucleotides, spatially scaffolding the binding partners, such as a nanobody, a peptide or DNA aptamers to
obtain increased binding through multimerisation. Multimerisation of the nanobody resulted in an increased binding affinity. The final project approached the employment of modified RNA
in standard applications, such as fibrillation assays and histochemistry. Small 𝛼-SN binding molecules were conjugated to RNA to study if the conjugation affected binding properties or
fibrillation of 𝛼-SN. And whether modified RNA could be utilised as an imaging agent of human tissue containing pathological 𝛼-SN. The application of modified RNA did not yield conclusive
results when investigating 𝛼-SN, as none of the RNA constructs exhibited the desired specificity.
Collectively, these projects demonstrate the potential of chemically modifying nucleic acids by altering the sequence in a site-specific manner or utilising oligonucleotides to scaffold binding
partners and detection agents. Nucleic acid scaffolds can display a diverse range of molecules with high spatial control, making them suitable for applications in bioimaging and molecular
targeting.
concerns. To date, diagnosis relies on clinical determination of symptoms that may develop decades after the disease’s onset. Biomarkers reflecting the progression of Parkinson’s disease
have arisen as potential diagnostic targets, such as 𝛼-Synuclein (𝛼-SN) aggregates. 𝛼-SN oligomers are small aggregated species which play a key role in disease initiation and progression.
These appear promising biomarkers for early detection, although specific targeting remains challenging.
Nucleic acid technology has transpired in diagnostic applications due to its unique properties of self-assembly and sequence programmability, facilitated by Watson-Crick base pairing, along
with the possibility of easy chemical functionalisation. Nucleic acids are commonly applied in biosensing and target recognition, as they can be utilised to build various architectures, either
binding a target specifically, such as aptamers, or scaffolding known binding partners.
This thesis presents three projects approaching specific targeting of 𝛼-SN by employing the functionalisation of nucleic acids. In the first project, RNA was modified in a site-specific manner
using small molecules reported to interact with 𝛼-SN. The modifications were incorporated, using the RNA as a spatially designed scaffold or employing systematic evolution of ligands
by exponential enrichment (SELEX) for specific targeting of 𝛼-SN. The incorporation of modifications did increase interactions of 𝛼-SN, though specificity was not obtained. The second
project applied the conjugation of known 𝛼-SN binding partners to DNA oligonucleotides, spatially scaffolding the binding partners, such as a nanobody, a peptide or DNA aptamers to
obtain increased binding through multimerisation. Multimerisation of the nanobody resulted in an increased binding affinity. The final project approached the employment of modified RNA
in standard applications, such as fibrillation assays and histochemistry. Small 𝛼-SN binding molecules were conjugated to RNA to study if the conjugation affected binding properties or
fibrillation of 𝛼-SN. And whether modified RNA could be utilised as an imaging agent of human tissue containing pathological 𝛼-SN. The application of modified RNA did not yield conclusive
results when investigating 𝛼-SN, as none of the RNA constructs exhibited the desired specificity.
Collectively, these projects demonstrate the potential of chemically modifying nucleic acids by altering the sequence in a site-specific manner or utilising oligonucleotides to scaffold binding
partners and detection agents. Nucleic acid scaffolds can display a diverse range of molecules with high spatial control, making them suitable for applications in bioimaging and molecular
targeting.
| Original language | English |
|---|---|
| Place of Publication | Aarhus |
| Publisher | |
| Publication status | Published - 2024 |